HAE
Strong BuyPremium GrowerAI screen passHaemonetics Corporation · Healthcare · United States · $5.4B cap · $81.8M/day traded
$118.51 +2.0% · close 23 Oct · scored 24 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
As of 24 Oct 2026, MoatMap's StockRank for Haemonetics Corporation (HAE) is 84/100, ranked against 24,000+ stocks in 35 markets (Quality 66, Value 35, Momentum 80, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Haemonetics clears the calibrated bar. All three legs are above the floor (Q69 V50 M64) and a buyback retiring 6.21% of shares outstanding in 90 days provides substantial corroboration, the largest single capital return in this batch. Nothing adverse is on file: no negative earnings revision and no insider selling. Blood management and plasma collection technology has a recurring disposables revenue base that is defensive.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT HAEMONETICS CORPORATION
Read
Haemonetics Corporation is a global healthcare company providing innovative blood management solutions, including blood and plasma collection, processing, and patient blood management devices. It is a leader in blood management technology, offering proprietary automated devices and consumables that optimize the collection and processing of blood components. Its specialized solutions address critical needs in healthcare, creating strong customer lock-in and a significant competitive moat.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 993.2M | 1.2B | 1.3B | 1.4B | 1.3B | 7.7% | 1.4B | 1.4B | 1.5B | 5.9% |
| EPS | 0.85 | 2.27 | 2.32 | 3.33 | 2.06 | 24.8% | 2.07 | 2.21 | 2.40 | 7.9% |
| Shares | 51.1M | 50.4M | 50.8M | 48.2M | 45.3M | -11.5% | 45.5M | — | — | — |
| Debt | 773.6M | 765.9M | 807.8M | 1.2B | 1.2B | 12.2% | 1.2B | — | — | — |
| Equity | 749.4M | 818.0M | 960.0M | 820.8M | 796.3M | 1.5% | — | — | — | — |
| Op CF | 172.3M | 273.1M | 181.8M | 181.7M | 293.2M | 14.2% | 328.1M | — | — | — |
| Inv CF | -86.3M | -143.8M | -322.4M | -161.9M | -179.5M | — | — | — | — | — |
| Fin CF | -15.7M | -100.4M | 38.2M | 108.8M | -178.5M | — | — | — | — | — |
Above its 200-day average and 4% below its 52-week high.
Swung more than 65% of stocks we rank over the past year (52% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HAE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HAE | Haemonetics Corporation(you) | $5.4B | 84 | Strong Buy |
| BIO-B | Bio-Rad Laboratories, Inc. | $8.3B | 76 | Buy |
| GMED | Globus Medical, Inc. | $10.9B | 89 | Strong Buy |
| ITGR | Integer Holdings Corporation | $4.3B | 68 | Buy |
| UFPT | UFP Technologies, Inc. | $2.3B | 80 | Strong Buy |
| INSP | Inspire Medical Systems, Inc. | $2.1B | 82 | Strong Buy |
| ZBH | Zimmer Biomet Holdings, Inc. | $18.8B | 88 | Strong Buy |
| STE | STERIS plc | $22.6B | 83 | Strong Buy |
| CNMD | CONMED Corporation | $1.5B | 92 | Strong Buy |
| DXCM | DexCom, Inc. | $29.4B | 81 | Strong Buy |
Peer medians: ROE -31.5% · P/E 27.3x · Gross margin 63.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.